Time to act in CKD: Finerenone as a pillar of treatment in T2D patients

Bayer AG |
Thursday

Chair: Lori Berard (CAN)

15:00 – 15:05Welcome and introductionLori Berard (CAN)
15:05 – 15:25

Round table

Time to act in CKD: Finerenone as a pillar of treatment in T2D patients

  • Time to act in T2D and CKD
  • The Heart of the Matter
  • The holistic approach for my T2D CKD patient

Ana Maria Cebrián Cuenca (ESP)

Paola Fioretto (ITA)

15:25 – 15:30Take home messagesLori Berard (CAN)